AprilBio Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 28

Employees

  • Stock Symbol
  • 397030

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $9.08
  • (As of Friday Closing)

AprilBio General Information

Description

AprilBio Co Ltd is a bio company is developing biologis. It owns long acting protein medicine platform technology utilizing human FAB antobody parts that makes unusual combination to serum akbumin and EX 12 helper phase antibody library technology.

Contact Information

Website
www.aprilbio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Room 602, Building B, Medical and Bioscience College, Gangwon University
  • 1 Gangwondaehak-gil (Hyoja-dong)
  • Chuncheon, Gangwon 24341
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Room 602, Building B, Medical and Bioscience College, Gangwon University
  • 1 Gangwondaehak-gil (Hyoja-dong)
  • Chuncheon, Gangwon 24341
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AprilBio Stock Performance

As of 13-Nov-2026, AprilBio’s stock price is $9.08. Its current market cap is $250M with 27.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.08 $9.09 $7.59 - $51.91 $250M 27.5M 241K -$0.27

AprilBio Financials Summary

As of 30-Jun-2026, AprilBio has a trailing 12-month revenue of $500K.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 561,843 808,165 191,753 226,451
Revenue 500 1,526 20,165
EBITDA (7,654) (8,257) 13,793 (11,988)
Net Income (6,210) (6,836) 14,662 (10,807)
Total Assets 63,733 67,444 67,617 61,848
Total Debt 344 346 2,108 4,581
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AprilBio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AprilBio‘s full profile, request access.

Request a free trial

AprilBio Patents

  • 61

    Total Documents Applications and Grants

  • Total Patents Families

  • 20

    Granted

  • 31

    Pending

  • Expiring in next 12 mo

AprilBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025253161-A1 Methods for treating liver diseases using recombinant fusion proteins comprising interleukin-18-binding protein and antigen binding fragment to serum albumin Pending 05-Jun-2024
AU-2024389296-A1 Fusion proteins for use in treatment of thyroid eye disease Pending 28-Nov-2023
EP-4816398-A1 Fusion proteins for use in treatment of thyroid eye disease Pending 28-Nov-2023
WO-2025114319-A1 Fusion proteins for use in treatment of thyroid eye disease Inactive 28-Nov-2023
AU-2023364925-A1 Fusion protein comprising interleukin-2 mutein and antigen-binding fragment to serum albumin and compositions and uses thereof Pending 19-Oct-2022 C07K14/55
To view AprilBio’s complete patent history, request access »

AprilBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AprilBio Investments (1)

AprilBio’s most recent deal was a Later Stage VC with Curigin for . The deal was made on 01-Apr-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Curigin 01-Apr-2026 Later Stage VC Drug Discovery
To view AprilBio’s complete investments history, request access »

AprilBio ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view AprilBio’s complete esg history, request access »

AprilBio FAQs

  • When was AprilBio founded?

    AprilBio was founded in 2013.

  • Where is AprilBio headquartered?

    AprilBio is headquartered in Chuncheon, South Korea.

  • What is the size of AprilBio?

    AprilBio has 28 total employees.

  • What industry is AprilBio in?

    AprilBio’s primary industry is Drug Discovery.

  • Is AprilBio a private or public company?

    AprilBio is a Public company.

  • What is AprilBio’s stock symbol?

    The ticker symbol for AprilBio is 397030.

  • What is the current stock price of AprilBio?

    As of 13-Nov-2026 the stock price of AprilBio is $9.08.

  • What is the current market cap of AprilBio?

    The current market capitalization of AprilBio is $250M.

  • What is AprilBio’s current revenue?

    The trailing twelve month revenue for AprilBio is $500K.

  • What is AprilBio’s annual earnings per share (EPS)?

    AprilBio’s EPS for 12 months was -$0.27.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process